Marty Vanderploeg
Analyst · Northland Securities. Your line is open.
Thanks for the question, Mike. I hope that came across pretty strong. ESG is, by far, our top priority this year. I think that -- like I've said in the past, I've spent so much time talking to ESG experts, regulators, people on all these different regulatory positions, senators in the U.S., I've just spent a ton of time feeling out this market. And it's clear this is going to happen. It's also clear that it's a very big market. And what's amazing, and we have a platform that we've invested from its inception over $600 million ready to go. Now that's -- like I've said earlier, that it's better to be lucky than good sometimes. I think we're both. We're very lucky, and we have a platform, all -- I mean, 90% there to take on this task. So yes, we are leaning in heavily. And everyone's saying these numbers have to be -- have assurance wrapped around them. That means controls and audit. And we're going to integrate our controls and audit product in so that we can assure all the ESG numbers. And we know how to report them to the jurisdictions like the SEC and the EU. So if there's ever been a time when Workiva can have a very large TAM and take a big chunk of the market, this is it. Now other things that we're doing are primarily platform focused. We -- when we can make our platform better it affects all of our use cases, our annual and interim reporting for private companies, our management reporting, our global statutory reporting all of our financial reporting. It impacts all of those things. So in terms of R&D, we're leaning in there. In terms of sales, we're continuing to enable and keep those salespeople focused and working to keep all those other bookings and revenue streams healthy, but -- yes, I mean, ESG is getting the lion's share of attention and investment right now because like I said, it's generational for us. It really is. And we're just in the driver seat. I was accused of being giddy a couple of calls ago. So I'm not going to be giddy but this is just fell in our lab, and we're not going to miss it. I think I would be remiss in my fiduciary responsibilities as running this company if we didn't make this investment so.